Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebirth: Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
NCT05531123Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Fudan University. Primary endpoint: Bladder Intact Disease-Free Survival at 1 year. Started Sep 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05531123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531123.